• What is CMT?
    • About CMT
    • Type1
      • What is CMT1A?
      • What is CMT1B?
      • What is CMT1E?
      • What is HNPP?
    • Type2
      • What is CMT2A?
    • Type4
      • What is SORD?
    • TypeX
      • Understanding CMT1X/CMTX1 and GJB1
    • —-
    • Watch Our Video Series
    • Learn About Treatments in Development
  • Research
    • Research Approach
    • Research Projects We Fund
    • Research Pipeline
    • Gene Therapy
    • Clinical Trials
    • —-
    • Apply for Funding
    • Young Researchers Innovation Grant
  • News & Stories
    • News
    • CMT Stories
  • Take Action
  • About Us
    • Who We Are
    • Board of Directors
    • Research Advisory Council
    • Scientific Advisory Board
    • Research Foundation Staff
    • Events
    • Financials
    • Contact Us
    • Global CMT Research Convention
  • Donate
Milestone 2 Completed for CMT1A Project from Cyprus Institute of Neurology and Genetics

Milestone 2 Completed for CMT1A Project from Cyprus Institute of Neurology and Genetics

Feb 12, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Research News

In February 2020, Dr. Kleopa completed milestone 2 of the 24-month project and the results continue to be encouraging.   The goal during this 6-12 month period of the project was to further optimize the amount of PMP22 gene silencing in a mouse model of CMT1A.    Dr....

Creating multiple opportunities for success in CMT 1A

Feb 12, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Foundation News

By Grace Pavlath, PhD By now you’ve likely heard that CMTRF is funding three genetic-based projects focused on therapy development for CMT1A:    DTx Pharma,  Shift Pharma and  Cyprus Institute of Neurology and Genetics.  Funding multiple complementary approaches gives...
CMT Research Foundation Funds Shift Pharmaceuticals to Advance Search for CMT1A Treatment

CMT Research Foundation Funds Shift Pharmaceuticals to Advance Search for CMT1A Treatment

Jan 30, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Foundation News, Research News

Shift to Develop and Analyze Novel Series of Drugs Designed to Control Expression of PMP22 Gene The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, today announced it has partnered with...

Importance of Biomarkers in CMT

Jan 21, 2020 | CMT Research Updates, Drug Development, Research News

By Grace Pavlath, PhD Because CMT is often a slowly progressive disease, measuring the impact of a potential treatment during a typical clinical trial of 12-24 months can be elusive.  Current clinical outcome measures are inadequate in detecting such progression and...

Targeting Axon Degeneration – a treatment for all types of CMT?

Jan 7, 2020 | CMT Research Updates, Research News

Can axon degeneration be prevented in CMT? By Dr. Grace Pavlath, PhD I’m often asked if a therapy for one type of CMT could be beneficial in another. There are over 100 different genes known to cause CMT; they either directly disrupt myelin or axon integrity of...
« Older Entries
Next Entries »

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Foundation News
  • Life with CMT
  • Research News

Help us find a cure.

Donate Now
Donate Now

Help us find a cure.

NEWSLETTER SIGNUP

Stay up to date on new CMT research, treatments and clinical trials



Address

4062 Peachtree Road
Suite A209
Atlanta, GA 30319



Phone Number

404.806.7180



EMAIL

[email protected]

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2025 CMT Research Foundation | Privacy Policy

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}